Jun-11 -

Genito-Urinary Group

EORTC 30894 – Phase III study of primary chemotherapy (CMV) in T2G3, T3 and T4a, NO-X, M0 transitional cell carcinoma of the bladder (MRC/EORTC Collaborative Study).

International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now National Cancer Research Institute Bladder Cancer Clinical Studies Group), EORTC GUTCG, the Australian Bladder Cancer Study Group, the NCI of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, & Club Urologico Espanol de Tratamiento Oncologico Group.

This international collaborative study that included EORTC, found that primary chemotherapy (CMV) before secondary treatment, reduced the risk of death by 16% in patients with muscle-invasive urothelial cancer. This was confirmed in a long-term follow up study and changed the standard of care to chemotherapy plus local therapy for invasive bladder cancer.


Go to Top